Magaldrate

Identification

Name
Magaldrate
Accession Number
DB08938
Type
Small Molecule
Groups
Approved, Withdrawn
Description

Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.

Structure
Thumb
Synonyms
  • Aluminium magnesium hydroxide sulfate hydrate
  • Aluminum magnesium hydroxide sulfate hydrate
  • Aluminum magnesium hydroxide sulphate hydrate
  • Hydrate magnesium aluminate activated sulfate
  • Magaldrato
  • Magaldratum
  • Magnesium aluminate hydrate
  • Monalium hydrate
External IDs
AY 5710 / AY-5710
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Riopan Chewable Tablets 480mgTablet480 mgOralWyeth Ayerst Canada Inc.1994-12-312002-07-31Canada
Riopan Sus 480mg/5mlSuspension480 mgOralWhitehall Robins Inc.1993-12-312002-07-19Canada
Riopan Suspension 480mg/5mlSuspension480 mgOralWyeth Ayerst Canada Inc.1994-12-312002-07-31Canada
Riopan Tab 480mgTablet480 mgOralWhitehall Robins Inc.1993-12-312002-07-19Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Riopan Plus SusMagaldrate (480 mg) + Dimethicone (20 mg)SuspensionOralWyeth Ayerst Canada Inc.1994-12-312002-07-31Canada
Riopan Plus SuspensionMagaldrate (96 mg) + Dimethicone (4 mg)SuspensionOralWhitehall Robins Inc.1993-12-312001-07-26Canada
Riopan Plus TabletsMagaldrate (480 mg) + Dimethicone (20 mg)TabletOralWhitehall Robins Inc.1993-12-311998-07-29Canada
Zantanol Tab.Magaldrate (50 mg/424mg) + Magnesium oxide (50 mg/424mg)TabletOralCho a pharm.co.,ltd.2017-02-28Not applicableUs
International/Other Brands
Almadrat T (Actavis) / Almagel T (Balkanpharma) / Antashin (Standard) / Bemolan (Nycomed) / Cremag (Zuoz) / Glysan (Riemser) / Lowsium (Rugby) / Magacid (Purzer) / Malugastrin (Polfa Lódz) / Riopan (Nycomed) / Sanaflat (Perumed)
Categories
UNII
6V88E24N5T
CAS number
74978-16-8
Weight
Average: 164.35
Monoisotopic: 163.9199523
Chemical Formula
AlHMgO5S
InChI Key
JIFPTBLGXRKRAO-UHFFFAOYSA-K
InChI
InChI=1S/Al.Mg.H2O4S.H2O/c;;1-5(2,3)4;/h;;(H2,1,2,3,4);1H2/q+3;+2;;/p-3
IUPAC Name
aluminium(3+) ion magnesium(2+) ion hydroxide sulfate
SMILES
[OH-].[Mg++].[Al+3].[O-]S([O-])(=O)=O

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Aluminium oxide: absorbed Al ions are eliminated in the urine (0.1-0.5 mg of Al in aluminium-containing antacid is absorbed from standard daily doses of antacid) while insoluble or poorly absorbed Al salts in the intestines are excreted through the feces.

Magnesium oxide: absorbed Mg ions (up to 30%) are eliminated in the urine, unabsorbed is excreted in the feces.

Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Magaldrate.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Magaldrate.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineMagaldrate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineMagaldrate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
3,4-MethylenedioxyamphetamineMagaldrate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMagaldrate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Magaldrate.Experimental, Illicit
AcepromazineMagaldrate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineMagaldrate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Magaldrate.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Magaldrate.Experimental, Investigational
AlimemazineMagaldrate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolMagaldrate can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Magaldrate.Approved
AmphetamineMagaldrate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit, Investigational
AndrostenedioneThe bioavailability of Androstenedione can be decreased when combined with Magaldrate.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Magaldrate.Investigational
anecortave acetateThe bioavailability of anecortave acetate can be decreased when combined with Magaldrate.Investigational
AtamestaneThe bioavailability of Atamestane can be decreased when combined with Magaldrate.Investigational
AtazanavirMagaldrate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Magaldrate.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magaldrate.Approved, Investigational
BenzphetamineMagaldrate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Magaldrate.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magaldrate.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Magaldrate.Approved, Investigational
BL-1020Magaldrate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Magaldrate.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Magaldrate.Approved
CaptoprilMagaldrate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Magaldrate.Approved, Investigational
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Magaldrate.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Magaldrate.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Magaldrate.Approved, Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Magaldrate.Approved, Investigational, Vet Approved
ChlorphentermineMagaldrate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineMagaldrate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineMagaldrate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlortetracyclineMagaldrate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Magaldrate.Approved, Investigational
CinoxacinMagaldrate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CiprofloxacinMagaldrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Magaldrate.Approved, Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Magaldrate.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Magaldrate.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Magaldrate.Approved
Cortexolone 17α-propionateThe bioavailability of Cortexolone 17α-propionate can be decreased when combined with Magaldrate.Investigational
CorticosteroneThe bioavailability of Corticosterone can be decreased when combined with Magaldrate.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Magaldrate.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Magaldrate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magaldrate.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Magaldrate.Approved, Investigational
DasatinibMagaldrate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magaldrate.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Magaldrate.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Magaldrate.Approved
DemeclocyclineMagaldrate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesonideThe bioavailability of Desonide can be decreased when combined with Magaldrate.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Magaldrate.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Magaldrate.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Magaldrate.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Magaldrate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Magaldrate.Vet Approved
DexmethylphenidateMagaldrate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DextroamphetamineMagaldrate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionMagaldrate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Magaldrate.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Magaldrate.Approved, Investigational, Withdrawn
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Magaldrate.Approved
Dipotassium phosphateMagaldrate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Magaldrate.Approved
DoxycyclineMagaldrate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Magaldrate.Approved
EnoxacinMagaldrate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EquileninThe bioavailability of Equilenin can be decreased when combined with Magaldrate.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Magaldrate.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Magaldrate.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Magaldrate.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Magaldrate.Approved
Ferric CarboxymaltoseMagaldrate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateMagaldrate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Magaldrate.Approved, Investigational
FleroxacinMagaldrate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluasteroneThe bioavailability of Fluasterone can be decreased when combined with Magaldrate.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Magaldrate.Approved, Investigational
FlumequineMagaldrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Magaldrate.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Magaldrate.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magaldrate.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Magaldrate.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Magaldrate.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Magaldrate.Approved, Investigational
FluphenazineMagaldrate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Magaldrate.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Magaldrate.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Magaldrate.Approved
FluticasoneThe bioavailability of Fluticasone can be decreased when combined with Magaldrate.Approved, Experimental, Investigational
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Magaldrate.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Magaldrate.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Magaldrate.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Magaldrate.Approved, Investigational, Withdrawn
FosinoprilMagaldrate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Magaldrate.Approved, Investigational
GarenoxacinMagaldrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinMagaldrate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Magaldrate.Approved, Investigational
GemifloxacinMagaldrate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineMagaldrate may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GrepafloxacinMagaldrate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Magaldrate.Approved, Investigational, Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Magaldrate.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Magaldrate.Approved, Vet Approved
HydroxyamphetamineMagaldrate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Magaldrate.Approved
Iofetamine I-123Magaldrate may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronMagaldrate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranMagaldrate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateMagaldrate can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidMagaldrate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Magaldrate.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Magaldrate.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Magaldrate.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Magaldrate.Approved
LevofloxacinMagaldrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LisdexamfetamineMagaldrate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LomefloxacinMagaldrate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Magaldrate.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Magaldrate.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Magaldrate.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Magaldrate.Approved, Investigational
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Magaldrate.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Magaldrate.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Magaldrate.Approved, Investigational
MephedroneMagaldrate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineMagaldrate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magaldrate.Approved
MesoridazineMagaldrate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethamphetamineMagaldrate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Magaldrate.Approved, Vet Approved
MethotrimeprazineMagaldrate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethoxyphenamineMagaldrate may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
Methylene blueMagaldrate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylphenidateMagaldrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Magaldrate.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Magaldrate.Experimental
MidomafetamineMagaldrate may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
MinocyclineMagaldrate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Magaldrate is combined with Misoprostol.Approved
MMDAMagaldrate may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Magaldrate.Approved, Vet Approved
MoricizineMagaldrate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
MoxifloxacinMagaldrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Mycophenolic acidMagaldrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidMagaldrate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Magaldrate.Investigational
NemonoxacinMagaldrate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Magaldrate.Approved, Investigational
NorfloxacinMagaldrate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OfloxacinMagaldrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl-estrone can be decreased when combined with Magaldrate.Investigational
Oxolinic acidMagaldrate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxytetracyclineMagaldrate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Magaldrate.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Magaldrate.Approved
PazufloxacinMagaldrate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinMagaldrate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Magaldrate.Approved
PerazineMagaldrate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerphenazineMagaldrate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineMagaldrate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
Pipemidic acidMagaldrate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidMagaldrate can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Magaldrate.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Magaldrate.Approved, Investigational, Nutraceutical
Prasterone sulfateThe bioavailability of Prasterone sulfate can be decreased when combined with Magaldrate.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Magaldrate.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Magaldrate.Approved, Investigational
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Magaldrate.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Magaldrate.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Magaldrate.Approved, Experimental, Investigational
ProchlorperazineMagaldrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineMagaldrate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineMagaldrate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropericiazineMagaldrate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropiopromazineMagaldrate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinMagaldrate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineMagaldrate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineMagaldrate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
QuinineThe serum concentration of Quinine can be decreased when it is combined with Magaldrate.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Magaldrate.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Magaldrate.Approved
RitobegronMagaldrate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinMagaldrate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Magaldrate.Approved
RufloxacinMagaldrate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Magaldrate.Approved
SitafloxacinMagaldrate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateMagaldrate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateMagaldrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Magaldrate.Approved
SparfloxacinMagaldrate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Magaldrate.Approved, Investigational
TemafloxacinMagaldrate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TetracyclineMagaldrate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ThiazinamMagaldrate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineMagaldrate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioproperazineMagaldrate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThioridazineMagaldrate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Magaldrate.Approved, Withdrawn
TolevamerThe risk or severity of adverse effects can be increased when Magaldrate is combined with Tolevamer.Approved, Investigational
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Magaldrate.Approved, Vet Approved
TriethylenetetramineMagaldrate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TrifluoperazineMagaldrate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TriflupromazineMagaldrate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinMagaldrate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Magaldrate.Approved
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 2,923,660.

General References
  1. Kurtz W: [A layered lattice antacid with long-term effectiveness. Profile of action and safety exemplified by magaldrate]. Fortschr Med. 1993 Feb 28;111(6):93-6. [PubMed:8462913]
  2. Varas Lorenzo MJ, Lopez Martinez A, Gordillo Bernal J, Mundet Surroca J: [Comparative study of 3 drugs (aceglutamide aluminum, zinc acexamate, and magaldrate) in the long-term maintenance treatment (1 year) of peptic ulcer]. Rev Esp Enferm Dig. 1991 Aug;80(2):91-4. [PubMed:1790087]
External Links
KEGG Drug
D04832
PubChem Compound
3086011
PubChem Substance
310264905
ChemSpider
2342732
Drugs.com
Drugs.com Drug Page
Wikipedia
Magaldrate
ATC Codes
A02AD02 — MagaldrateA02AF01 — Magaldrate and antiflatulents
MSDS
Download (94.8 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionOral
TabletOral
SuspensionOral480 mg
TabletOral480 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as post-transition metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is a post-transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Post-transition metal oxoanionic compounds
Sub Class
Post-transition metal sulfates
Direct Parent
Post-transition metal sulfates
Alternative Parents
Post-transition metal salts / Inorganic salts / Inorganic oxides / Inorganic hydrides
Substituents
Post-transition metal sulfate / Inorganic post-transition metal salt / Inorganic hydride / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on May 22, 2014 13:08 / Updated on June 02, 2018 08:14